Galectin Therapeutics Q3 EPS $(0.14), Same YoY
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers
Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.
62 Biggest Movers From Yesterday
Gainers
Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to $11
HC Wainwright & Co. analyst Ed Arce maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and lowers the price target from $14 to $11.
Recap: Galectin Therapeutics Q1 Earnings
Galectin Therapeutics (NASDAQ:GALT) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Galectin Therapeutics Q1 EPS $(0.17) Down From $(0.11) YoY
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.17) per share. This is a 54.55 percent decrease over losses of $(0.11) per share from the same period last year.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
